Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
6.74B
Market cap6.74B
Price-Earnings ratio
-37.42
Price-Earnings ratio-37.42
Dividend yield
Dividend yield
Average volume
1.35M
Average volume1.35M
High today
$142.61
High today$142.61
Low today
$133.95
Low today$133.95
Open price
$140.55
Open price$140.55
Volume
801.28K
Volume801.28K
52 Week high
$151.02
52 Week high$151.02
52 Week low
$9.51
52 Week low$9.51

Stock Snapshot

Celcuity(CELC) stock is priced at $139.44, giving the company a market capitalization of 6.74B. It carries a P/E multiple of -37.42.

On 2026-05-06, Celcuity(CELC) stock traded between a low of $133.95 and a high of $142.61. Shares are currently priced at $139.44, which is +4.1% above the low and -2.2% below the high.

The Celcuity(CELC)'s current trading volume is 801.28K, compared to an average daily volume of 1.35M.

During the past year, Celcuity(CELC) stock moved between $9.51 at its lowest and $151.02 at its peak.

During the past year, Celcuity(CELC) stock moved between $9.51 at its lowest and $151.02 at its peak.

CELC News

TipRanks 2d
Celcuity rises 18.4%

Celcuity (CELC) is up 18.4%, or $23.07 to $148.72. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-perfo...

Benzinga 3d
Why Is Celcuity Stock Rallying Today?

Celcuity Inc. (NASDAQ:CELC) shares are up during Monday’s premarket session following positive news about its Phase 3 VIKTORIA-1 trial results. The stock’s move...

Why Is Celcuity Stock Rallying Today?
TipRanks 5d
Celcuity Reports Positive Phase 3 Results for Gedatolisib

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

More CELC News

TipRanks 5d
Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint

Celcuity (CELC) announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestran...

Simply Wall St 6d
Celcuity Is Up 6.9% After FDA Grants Priority Review For Gedatolisib And Debt Financing - Has The Bull Case Changed?

In recent months, Celcuity Inc. announced that the FDA granted Priority Review for its lead breast cancer drug candidate gedatolisib, with a PDUFA goal date set...

Celcuity Is Up 6.9% After FDA Grants Priority Review For Gedatolisib And Debt Financing - Has The Bull Case Changed?

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.